Trial Profile
A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tomaralimab (Primary) ; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Opsona Therapeutics
- 04 Dec 2018 Results (n=51) reporting response data in an expanded 10 mg/kg Tomaralimab in Myelodysplastic Syndrome patients that failed Hypomethylating Agent therapy, cohort presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 30 Nov 2018 Planned number of patients changed from 40 to 52.
- 30 Nov 2018 Status changed from recruiting to active, no longer recruiting.